Send Your Enquiry
About Dr. Srividya Nasaka
- Dr. Srividya Nasaka is a Medical Oncologist in India.
- She has 10 years of rich experience in her field.
- She is an expert in Breast oncology and Gynecological Oncology, Preventive Oncology, Chemotherapy, Targeted therapy, Immunotherapy in the management of breast, lung, gastrointestinal, genitourinary, bone cancers.
- Dr. Srividya Nasaka has several publications, journals, and articles to her name.
- She has completed MBBS from Andhra Medical College, Visakhapatnam, Andhra Pradesh, India.
- She did MD from Kasturba Medical College, Mangalore, India.
- She later pursued DM(Medical Oncology) from Nizam's Institute Of Medical Sciences, Hyderabad, India.
- She later did Fellowship (2015) from Royal Adelaide Hospital (RAH), Adelaide, Australia.
- Dr. Srividya Nasaka is well-versed in Hindi, Telugu and English.
Location
DM, Nizam's Institute Of Medical Sciences, Hyderabad, India- MD, Kasturba Medical College, Mangalore, India
- MBBS, Andhra Medical College, Visakhapatnam, Andhra Pradesh, India
- Consultant, HCG Curie City Cancer Center, Vijayawada, India
Papers Published
- Response to Imatinib Mesylate in Childhood Chronic Myeloid Leukemia in Chronic Phase”, South Asian J Cancer 2014 Oct;3(4):203-5.
- Impact of Imatinib compliance on the cytogenetic response at six months in pediatric CML CP. Indian Journal of Pediatrics 2016 Feb 3. DOI 10.1007/s12098-015-2007-9.
- Impact of treatment protocol on outcome of localized Ewing’s sarcoma. South Asian J Cancer 2016;5:194-5
- Trends in management of acute lymphoblastic leukemia: Influence of Insurance based healthcare and treatment compliance on the outcome of adolescents and aduls with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 2016 Jan-Mar; 37 (1):32-7
- Cytogenetic and Molecular response among EUTOS risk groups in children with CML CP on Imatinib treatment. Egypt J Haematol 2017;42:74-7.
- Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric CML CP on frontline Imatinib. Indian J Med Paediatr Oncol 2017;38:282-6.Imatinib dose hike in suboptimal response and failure in CML CP: Results from a developing nation. journal of Clinical oncology 31,2013_suppl e18003
- Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
- Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN): Single center, retrospective study. Annals of Oncology, Volume 29, Issue suppl_9, November 2018, mdy438.029.
- Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.
Send Your Enquiry
Fill in your details and our medical experts will contact you within 24 hours.
Want to consult the doctor?
Don't Ignore Your Health!
Other Top Medical Oncologist In Nellore
ChatFAQ's About Dr. Srividya Nasaka
Where does Dr. Srividya Nasaka practice?
Dr. Srividya Nasaka practices at Medicover Hospitals, Nellore
What is the specialty of Dr. Srividya Nasaka?
Dr. Srividya Nasaka specialty is Medical Oncologist
What is the experience of Dr. Srividya Nasaka?
Dr. Srividya Nasaka is Medical Oncologist with 13 years of experience.
Chat